Valuation: Biocept Inc

Market Cap 110K 94.48K 88.4K 80.92K 152K 10.55M 154K 1.04M 407K 5.3M 414K 405K 17.53M P/E 2021
-18.9x
P/E 2022 -0.28x
Enterprise Value -678K -581K -543K -497K -933K -64.84M -945K -6.42M -2.5M -32.57M -2.54M -2.49M -108M EV / Sales 2021
0.73x
EV / Sales 2022 0.32x
Free-Float
100%
Yield 2021 *
-
Yield 2022 -
Change 5-day change 1-year change 3-year change Capi.($)
-4.27%-11.63% - - 262
+1.67%+8.57%+178.54%+352.16% 22.53B
-0.13%+1.92%-41.52%-19.91% 10.25B
+1.96%+16.10%+397.10%+40.59% 8.32B
+6.88%+20.50%-31.09% - 6.95B
-0.27%-0.97%+68.98%+48.50% 6.54B
-4.95%+1.23%-12.97%-3.17% 6.37B
+1.49%-3.43%+69.95%+106.00% 4.34B
+0.56%+0.97%-12.93%-15.99% 4.32B
-0.86%+2.76%-17.52%-26.19% 2.97B
Average +0.21%+4.35%+66.50%+60.25% 8.07B
Weighted average by Cap. +1.01%+5.82%+99.86%+132.19%

Financials

2021 2022
Net sales 61.25M 52.47M 49.09M 44.94M 84.33M 5.86B 85.45M 580M 226M 2.94B 230M 225M 9.74B 25.86M 22.15M 20.73M 18.97M 35.6M 2.47B 36.07M 245M 95.49M 1.24B 97.09M 94.98M 4.11B
Net income -2.82M -2.42M -2.26M -2.07M -3.89M -270M -3.94M -26.74M -10.43M -136M -10.6M -10.37M -449M -32.09M -27.49M -25.72M -23.54M -44.18M -3.07B -44.76M -304M -118M -1.54B -120M -118M -5.1B
Net Debt -16.19M -13.87M -12.98M -11.88M -22.29M -1.55B -22.59M -153M -59.79M -778M -60.8M -59.47M -2.57B -788K -675K -632K -578K -1.09M -75.4M -1.1M -7.46M -2.91M -37.87M -2.96M -2.89M -125M
Logo Biocept Inc
Biocept, Inc. is a molecular diagnostics company with commercialized assays for patients with carcinomas or melanomas. The Company has developed a patented methodology to isolate cancer material that is shed from the primary tumor, such as CSF tumor cells (CSF-TCs) and cell-free DNA (cfDNA). As such, it is a commercial provider of testing services designed to enable clinicians to rapidly detect and monitor cancer biomarkers from a cerebrospinal fluid sample. The Company operates a clinical laboratory and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. The assays the Company offers are classified as laboratory developed tests (LDT) under the CLIA regulations. The Company’s assays, performed on cerebral spinal fluid, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease.
Employees
-